Literature DB >> 24686056

ALOX12 in human toxoplasmosis.

William H Witola1, Susan Ruosu Liu1, Alexandre Montpetit2, Ruth Welti3, Magali Hypolite4, Mary Roth3, Ying Zhou1, Ernest Mui1, Marie-France Cesbron-Delauw5, Gilbert J Fournie6, Pierre Cavailles5, Cordelia Bisanz5, Kenneth Boyer7, Shawn Withers1, A Gwendolyn Noble8, Charles N Swisher8, Peter T Heydemann7, Peter Rabiah9, Stephen P Muench10, Rima McLeod11.   

Abstract

ALOX12 is a gene encoding arachidonate 12-lipoxygenase (12-LOX), a member of a nonheme lipoxygenase family of dioxygenases. ALOX12 catalyzes the addition of oxygen to arachidonic acid, producing 12-hydroperoxyeicosatetraenoic acid (12-HPETE), which can be reduced to the eicosanoid 12-HETE (12-hydroxyeicosatetraenoic acid). 12-HETE acts in diverse cellular processes, including catecholamine synthesis, vasoconstriction, neuronal function, and inflammation. Consistent with effects on these fundamental mechanisms, allelic variants of ALOX12 are associated with diseases including schizophrenia, atherosclerosis, and cancers, but the mechanisms have not been defined. Toxoplasma gondii is an apicomplexan parasite that causes morbidity and mortality and stimulates an innate and adaptive immune inflammatory reaction. Recently, it has been shown that a gene region known as Toxo1 is critical for susceptibility or resistance to T. gondii infection in rats. An orthologous gene region with ALOX12 centromeric is also present in humans. Here we report that the human ALOX12 gene has susceptibility alleles for human congenital toxoplasmosis (rs6502997 [P, <0.000309], rs312462 [P, <0.028499], rs6502998 [P, <0.029794], and rs434473 [P, <0.038516]). A human monocytic cell line was genetically engineered using lentivirus RNA interference to knock down ALOX12. In ALOX12 knockdown cells, ALOX12 RNA expression decreased and levels of the ALOX12 substrate, arachidonic acid, increased. ALOX12 knockdown attenuated the progression of T. gondii infection and resulted in greater parasite burdens but decreased consequent late cell death of the human monocytic cell line. These findings suggest that ALOX12 influences host responses to T. gondii infection in human cells. ALOX12 has been shown in other studies to be important in numerous diseases. Here we demonstrate the critical role ALOX12 plays in T. gondii infection in humans.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24686056      PMCID: PMC4097613          DOI: 10.1128/IAI.01505-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

Review 1.  Arachidonic acid as a bioactive molecule.

Authors:  A R Brash
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells.

Authors:  William H Witola; Ernest Mui; Aubrey Hargrave; Susan Liu; Magali Hypolite; Alexandre Montpetit; Pierre Cavailles; Cordelia Bisanz; Marie-France Cesbron-Delauw; Gilbert J Fournié; Rima McLeod
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

3.  12-HETE and 12-HPETE potently stimulate intracellular release of calcium in intact human neutrophils.

Authors:  D Reynaud; C R Pace-Asciak
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1997-01       Impact factor: 4.006

4.  Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity.

Authors:  M Chen; Z D Yang; K M Smith; J D Carter; J L Nadler
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

5.  Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells.

Authors:  D Bleich; S Chen; J L Gu; L Thomas; S Scott; N Gonzales; R Natarajan; J L Nadler
Journal:  Endocrinology       Date:  1995-12       Impact factor: 4.736

Review 6.  NALPs: a novel protein family involved in inflammation.

Authors:  Jürg Tschopp; Fabio Martinon; Kimberly Burns
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

7.  Dual metabolic pathways of 12-HETE in rat aortic smooth muscle cells.

Authors:  G Lacape; D Daret; R Crockett; M Rigaud; J Larrue
Journal:  Prostaglandins       Date:  1992-09

8.  Neurologic and developmental outcome in treated congenital toxoplasmosis.

Authors:  N Roizen; C N Swisher; M A Stein; J Hopkins; K M Boyer; E Holfels; M B Mets; L Stein; D Patel; P Meier
Journal:  Pediatrics       Date:  1995-01       Impact factor: 7.124

9.  Effect of normal and activated human macrophages on Toxoplasma gondii.

Authors:  S E Anderson; J S Remington
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity.

Authors:  E C Yong; E Y Chi; W R Henderson
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Toxoplasmosis in Germany.

Authors:  Uwe Pleyer; Uwe Gross; Dirk Schlüter; Henrik Wilking; Frank Seeber
Journal:  Dtsch Arztebl Int       Date:  2019-06-21       Impact factor: 5.594

2.  Inherent Oxidative Stress in the Lewis Rat Is Associated with Resistance to Toxoplasmosis.

Authors:  William H Witola; Chi Yong Kim; Xuejin Zhang
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

3.  Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis.

Authors:  C A Naranjo-Galvis; A de-la-Torre; L E Mantilla-Muriel; L Beltrán-Angarita; X Elcoroaristizabal-Martín; R McLeod; N Alliey-Rodriguez; I J Begeman; C López de Mesa; J E Gómez-Marín; J C Sepúlveda-Arias
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

Review 4.  Host cell proteins modulated upon Toxoplasma infection identified using proteomic approaches: a molecular rationale.

Authors:  Sajad Rashidi; Carmen Vieira; Reza Mansouri; Mohammad Ali-Hassanzadeh; Esmaeel Ghani; Mohammadreza Karimazar; Paul Nguewa; Raúl Manzano-Román
Journal:  Parasitol Res       Date:  2022-05-13       Impact factor: 2.289

5.  Small GTPase Immunity-Associated Proteins Mediate Resistance to Toxoplasma gondii Infection in Lewis Rat.

Authors:  Chi Yong Kim; Xuejin Zhang; William H Witola
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

Review 6.  Mammalian lipoxygenases and their biological relevance.

Authors:  Hartmut Kuhn; Swathi Banthiya; Klaus van Leyen
Journal:  Biochim Biophys Acta       Date:  2014-10-12

Review 7.  The role of lipoxygenases in pathophysiology; new insights and future perspectives.

Authors:  Ryuichi Mashima; Torayuki Okuyama
Journal:  Redox Biol       Date:  2015-08-07       Impact factor: 11.799

Review 8.  The human immune response to Toxoplasma: Autophagy versus cell death.

Authors:  Shruthi Krishnamurthy; Eleni K Konstantinou; Lucy H Young; Daniel A Gold; Jeroen P J Saeij
Journal:  PLoS Pathog       Date:  2017-03-09       Impact factor: 6.823

9.  Toxoplasma Hypervirulence in the Rat Model Parallels Human Infection and Is Modulated by the Toxo1 Locus.

Authors:  Corinne Loeuillet; Anais Mondon; Salima Kamche; Véronique Curri; Jean Boutonnat; Pierre Cavaillès; Marie-France Cesbron-Delauw
Journal:  Front Cell Infect Microbiol       Date:  2019-05-01       Impact factor: 5.293

10.  Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Authors:  Huân M Ngô; Ying Zhou; Hernan Lorenzi; Kai Wang; Taek-Kyun Kim; Yong Zhou; Kamal El Bissati; Ernest Mui; Laura Fraczek; Seesandra V Rajagopala; Craig W Roberts; Fiona L Henriquez; Alexandre Montpetit; Jenefer M Blackwell; Sarra E Jamieson; Kelsey Wheeler; Ian J Begeman; Carlos Naranjo-Galvis; Ney Alliey-Rodriguez; Roderick G Davis; Liliana Soroceanu; Charles Cobbs; Dennis A Steindler; Kenneth Boyer; A Gwendolyn Noble; Charles N Swisher; Peter T Heydemann; Peter Rabiah; Shawn Withers; Patricia Soteropoulos; Leroy Hood; Rima McLeod
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.